Lipomel (Peptide Immune Ligands)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLipomel (Peptide Immune Ligands)
Drug Alias NameMelanoma vaccine (Peptide Immune Ligands)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesInstitute of Immunology and Infection, Chinese Academy of Sciences ShanghaiCentre National De La Recherche Scientifique (Cnrs)Inserm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentre National De La Recherche Scientifique (Cnrs)Peptide Immune LigandsInserm +[4] 
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A